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In 1903 Sir William Osler wrote “the good physician treats the disease; the great 
physician treats the patient who has the disease”.  These words ring very true in 
2016 as we approach the era of precision or stratified medicine.  The precision or 
stratified medicine (we are going to use these terms interchangeably) is based on 
identifying subgroups of patients with distinct mechanisms of disease and particular 
responses to treatments.  This allows us to identify and develop treatments that are 
effective for particular groups of patients.  Ultimately precision medicine will ensure 
that the right patient gets the right treatment at the right time.  The above definition 
broadly follows suggested definition published by the UK Medical Research Council 
(http://www.mrc.ac.uk/research/initiatives/stratified-medicine/). We can therefore 
summarise the promise of precision medicine as being able to remove non-
responders and toxic responders prior to prescribing medication and to treat with a 
given drug only responders and patients not predisposed to toxicity. 
 
Such approaches are very well developed in cancer medicine with several examples 
of successful precision medicine applications in breast, prostate, ovarian, colon and 
pancreatic cancer 1-6 and this list is by no means complete.  Cardiovascular medicine 
in general and hypertension in particular both lag behind oncology in this respect. 
 
However, there are examples from rare monogenic syndromes, where a single 
genetic mutation explains the entire pathophysiology of severe, early onset 
hypertension as well as dictating perfect pharmacogenetics-led prescription 7,8.  
These syndromes include the Glucocorticoid Remediable Aldosteronism, Liddle’s 
Syndrome and pseudohypoaldosteronism type II to name just a few.  In these 
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syndromes glucocorticoids, amiloride and thiazide diuretics, respectively are the 
pharmacogenetics-led prescriptions, based on our detailed understanding of the 
genetic pathophysiology of each syndrome 7,8. 
 
It is much more difficult to apply similar principles to the much more common primary 
or essential hypertension and yet the current approach of prescribing the same or 
nearly the same treatment for all is not sustainable long-term.  The methodology, 
which has brought significant progress in genomics of hypertension is the genome 
wide association study (GWAS).  In a classic GWAS thousands of patients and 
controls are included in a three-phase design, where data from the discovery cohort 
are first reproduced and then validated on separate, large cohorts of cases and 
controls. The GWAS requires 500,000-2,500,000 markers, known as single 
nucleotide polymorphisms (SNPs) with a good genome-wide coverage.  The “hits” 
are presented in a format called a Manhattan plot with p values of 10-8 or below 
normally considered to achieve a genome-wide significance. 
 
Several GWAS have been published followed by well-designed meta-analyses 9-13.  
The early GWAS for hypertension within the Wellcome Trust Case-Control 
Consortium was negative 9 most likely due to inclusion of hypertensive subjects in 
the control group, although other causes such as lack of power and relatively low 
number (500,000) of SNPs should also be considered 9.  The first successful GWAS 
meta-analysis included some 200,000 subjects and identified 29 genomic regions 
associated with blood pressure (BP) sub-phenotypes and hypertension as a binary 
trait 12.  The contribution of each individual SNP was approximately 1 mmHg for 
systolic and 0.5 mmHg for diastolic BP 12. The weighted genetic risk scores (GRS), 
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which were calculated for all 29 SNPs, showed highly significant associations with 
coronary heart disease, left ventricular hypertrophy and stroke but not with markers 
of renal function 12. The quality and the breadth of phenotyping in these very large, 
multi-centre studies is not perfect, with the limited number of BP and other 
phenotypes used 14. It is possible that the relative deficiency of more difficult to 
measure renal biomarkers have led to weaker risk scores related to kidney function.  
 
Further data with potential clinical significance have been generated by even larger 
meta-analyses published recently 15-17. In one of these studies, Surendran et al,15 
genotyped nearly 350,000 individuals to identify 30 new blood pressure or 
hypertension-associated risk loci. These analyses provide insights into the 
pathophysiology of hypertension thus highlighting new potential for precision 
medicine and for druggable targets 15.  The second study by Ehret et al., 16 
performed association analyses on 340,000 individuals and identified 66 loci; of 
which 17 were novel, involved in BP regulation. The 66 index SNPs combined in a 
risk score showed comparable effects in nearly 65,000 individuals from non-
European descent 16.  Similarly to previous studies, 66-SNP GRS was significantly 
associated with target organ damage in multiple tissues but with minor effects in the 
kidney 16. The third study by Liu et al. 17 identified 31 new loci, which were enriched 
for known variants for cardiometabolic traits. In addition, blood pressure associations 
at 39 previously published loci were confirmed. These large meta-analyses have 
increased the number of loci associated with BP regulation to 120 with 3.5% of the 
trait variance now explained 15-17. 
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In parallel experiments, functional data of potential clinical significance have been 
published using smaller but perfectly selected and phenotyped cohorts.  One good 
example here is the GWAS of blood pressure extremes, which identified variants in 
the uromodulin gene (UMOD) associated with hypertension 18. The special feature of 
this study was the selection of 2000 so called hypercontrols, subjects who had BP 
below 120/80 mmHg and were free from cardiovascular events during 10 year 
follow-up 19.  The uromodulin gene and protein are selectively expressed in the thick 
ascending loop of Henle (Figure 1), the part of the nephron responsible for 25% of 
sodium reabsorption in the kidney 8,18,20,21. Experiments with Umod knock-out mice 
showed not only a highly significant BP difference between the Umod +/+ and Umod 
-/- mice but also revealed that the knock-out mice are unable to increase their BP in 
response to 2% NaCl 21. Trudu et al 22 performed elegant experiments, which 
showed that UMOD polymorphisms are associated with a differential BP response to 
loop diuretics (the specific blocker of the main sodium channel in the thick ascending 
limb of the loop of Henle, NKCC2) in patients with essential hypertension 22. GWAS 
studies have been fruitful in discovering novel and robust associations with common 
traits. However, major challenges exist in identifying causal variants and 
demonstrating their functional mechanisms together with clinical translation. The 
novel implication from studies of Padmanabhan et al 18,20,21 and Trudu et al 22 is that 
based on UMOD rs13333226 genotype, there are two strata of hypertensive 
patients. The high-UMOD group (AA genotype) has increased UMOD excretion, 
greater salt sensitivity, hypertension, normal estimated glomerular filtration rate 
(eGFR) and greater BP response to loop diuretics. The low-UMOD group has 
decreased UMOD excretion, salt resistance increased eGFR, increased proximal 
tubular reabsorption of Na+ (possibly related to increased GFR), a poor BP response 
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to loop diuretics and a diminished function of NKCC2. These two contrasting strata 
present an opportunity for hypertension precision medicine. Volume overload is one 
of underlying causes for uncontrolled hypertension and yet loop diuretics, which are 
the most effective diuretics, are rarely used in hypertension without edema, heart 
failure or chronic kidney disease. A prospective genotype directed trial of a long-
acting loop diuretic, torasemide in uncontrolled hypertensive patients will confirm or 
refute the hypothesis that the AA – high UMOD genotype patients are good 
responders to loop diuretics. It will simultaneously confirm that the UMOD-NKCC2 
interaction is one of the mechanisms of salt-sensitivity. This precision medicine trial 
has been recently funded by the British Heart Foundation (CS.16/1/31878). Other 
areas for clinical and preclinical mechanistic studies include hepsin, the newly 
discovered protease that cleaves UMOD from its  glycophosphatidylinositol (GPI) 
anchor, other transporters that may influence NKCC2 function – ROMK, 
Na+/K+ATPase or chloride channels; tubulo-glomerular feedback or other proteins 
23,24. This molecular context of UMOD function is depicted in Figure 1. 
 
Whilst this and other similar studies are in progress, it is important to recognise that 
in addition to generating evidence for stratified or precision therapy, it is essential to 
show that the stratifier demonstrates increased cost-effectiveness, and improved 
quality of care.  
Dzau et al 25  analysed data from the Health Economics Medical Innovation 
Simulation, a pre-existing health simulation model, to assess the benefits and cost of 
personalized precision medicine innovations that would potentially improve 
identification and screening of presymptomatic, high risk patients. They calculated 
health generated value expressed as quality-adjusted life years (QALYs). The QALY 
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concept is being widely used in health economic modelling as it measures the effects 
of disease burden on quantity (life span) and quality of life. These measurements 
modelled over nearly a 50 year period, showed that even a 10% reduction in one of 
the six diseases - cancer, diabetes, heart disease, stroke, lung disease and 
hypertension could potentially save between $33 to $114 billion, in the form of longer 
and healthier lives (Figure 2). Hypertension and heart disease demonstrate the 
greatest value, primarily due to their high prevalence. It is clear from this modelling 
that with 10% incidence reduction for hypertension, the value of health is identical to 
similar incidence reduction in cancer 25. Even more striking are data that could be 
generated with 50% incidence reduction, where value of health for hypertension is 
almost double of the same value modelled for cancer 25. These are very important 
considerations for policy makers in health systems around the world. 
 
We believe that precision medicine as applied to cardiovascular disease in general 
and hypertension in particular is here to stay.  It will require major national and 
international collaborations between clinical academic centres, health systems and 
industry.  One excellent example of such national effort is the Scottish Ecosystem for 
Precision Medicine (http://www.imperial.ac.uk/media/imperial-college/institute-of-global-
health-innovation/Precision_Medicine_Report.pdf). Using excellent and Scotland-wide 
electronic health records together with highly collaborative four clinical academic 
centres and the National Health Service (NHS) free at the point of delivery, we are 
able to jointly create an excellent system to tackle multiple chronic diseases and 
cancer with precision medicine tools. Other examples include the UK Catapult for 
Precision Medicine (http://pm.catapult.org.uk) and President Obama’s Precision 
Medicine initiative in the United States 26. 
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In summary, the time is right for hypertension researchers to develop precision 
medicine tools for patients with essential or primary hypertension. These tools will be 
heavily based on genomics, at least initially, but there is growing evidence that other 
omics, including transcriptomics, proteomics and metabolomics will be increasingly 
used in combination with whole genome sequencing to facilitate disease 
stratification, early diagnostics and the precision prevention of hypertension and its 
complications. 
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Figure Legends 
 
Figure 1. Molecular context of UMOD in the thick ascending limb of loop of Henle 
cells. UMOD indicates the uromodulin gene, ClC-Ka indicates chloride channel 
protein class Ka; Clc-Kb, chloride channel protein class Kb; E.R., endoplasmic 
reticulum; GPI, glycosylphosphatidylinositol; NKCC2, Na+ K+ 2Cl− cotransporter 2; 
and ROMK, renal outer medullary potassium channel. Reprinted from “Uromodulin, 
an emerging novel pathway for blood pressure regulation and hypertension” by 
Padmanabhan et al, Hypertension 2014;64:918. Copyright 2014 by Wolters Kluwer 
Health. Reprinted with permission 
 
Figure 2. Value of health from hypothetical personalised and precision medicine 
prevention innovation at two levels of incidence reduction in six diseases in the USA 
($ billions). Value of health is measured in the quality–adjusted life-years (QALYs), 
which estimates the effects of disease burden on the quantity (life span) and quality 
of life. Reprinted from “Aligning incentives to fulfil the promise of personalised 
medicine” by Dzau et al, Lancet 2015;385:2118.Copyright 2015 by Elsevier. Health. 
Reprinted with permission 
 
 


